| Dr Shavaun Venoris Cotton, MD, MPH | |
|
3801 North Blvd, Baton Rouge, LA 70806-3825 | |
| (225) 387-7899 | |
| Not Available |
| Full Name | Dr Shavaun Venoris Cotton |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 12 Years |
| Location | 3801 North Blvd, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497014112 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD.207256 (Louisiana) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baton Rouge General Medical Center | Baton rouge, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baton Rouge General Physicians Inc | 5193623643 | 95 |
News Archive
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.
A new study in the June issue of Cell Metabolism, a Cell Press publication, sheds light on the action of the drug ezetimibe (trade name Zetia), which is used to treat high cholesterol. Ezetimibe is unique among cholesterol-lowering drugs in that it works by cutting the amount of cholesterol taken in from the diet rather than by blocking cholesterol's manufacture in the body.
Implementation of an algorithm aimed to diagnose pediatric patients with suspected appendicitis reduces the utilization of computed tomography (CT) scans, without affecting diagnostic accuracy, Mayo Clinic Children's Center researchers have found. The study was recently published in the journal Surgery.
› Verified 5 days ago
| Entity Name | Baton Rouge General Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992729560 PECOS PAC ID: 5193623643 Enrollment ID: O20040616000064 |
News Archive
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.
A new study in the June issue of Cell Metabolism, a Cell Press publication, sheds light on the action of the drug ezetimibe (trade name Zetia), which is used to treat high cholesterol. Ezetimibe is unique among cholesterol-lowering drugs in that it works by cutting the amount of cholesterol taken in from the diet rather than by blocking cholesterol's manufacture in the body.
Implementation of an algorithm aimed to diagnose pediatric patients with suspected appendicitis reduces the utilization of computed tomography (CT) scans, without affecting diagnostic accuracy, Mayo Clinic Children's Center researchers have found. The study was recently published in the journal Surgery.
› Verified 5 days ago
| Entity Name | Convenient Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164422630 PECOS PAC ID: 1153306816 Enrollment ID: O20040618000886 |
News Archive
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.
A new study in the June issue of Cell Metabolism, a Cell Press publication, sheds light on the action of the drug ezetimibe (trade name Zetia), which is used to treat high cholesterol. Ezetimibe is unique among cholesterol-lowering drugs in that it works by cutting the amount of cholesterol taken in from the diet rather than by blocking cholesterol's manufacture in the body.
Implementation of an algorithm aimed to diagnose pediatric patients with suspected appendicitis reduces the utilization of computed tomography (CT) scans, without affecting diagnostic accuracy, Mayo Clinic Children's Center researchers have found. The study was recently published in the journal Surgery.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shavaun Venoris Cotton, MD, MPH 3801 North Blvd, Baton Rouge, LA 70806-3825 Ph: (225) 387-7899 | Dr Shavaun Venoris Cotton, MD, MPH 3801 North Blvd, Baton Rouge, LA 70806-3825 Ph: (225) 387-7899 |
News Archive
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.
A new study in the June issue of Cell Metabolism, a Cell Press publication, sheds light on the action of the drug ezetimibe (trade name Zetia), which is used to treat high cholesterol. Ezetimibe is unique among cholesterol-lowering drugs in that it works by cutting the amount of cholesterol taken in from the diet rather than by blocking cholesterol's manufacture in the body.
Implementation of an algorithm aimed to diagnose pediatric patients with suspected appendicitis reduces the utilization of computed tomography (CT) scans, without affecting diagnostic accuracy, Mayo Clinic Children's Center researchers have found. The study was recently published in the journal Surgery.
› Verified 5 days ago
Dr. Roderick A. Hart Sr., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3801 North Blvd, Baton Rouge, LA 70806 Phone: 601-454-9462 | |
Dr. Brent Oliver Campanella, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5131 Essen Ln, Baton Rouge, LA 70809 Phone: 225-769-0043 Fax: 225-769-0133 | |
Robert Dwight Brower, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7037 Woodstock Dr, Baton Rouge, LA 70809 Phone: 225-975-8680 | |
Kristin Wemple Morvant, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 16777 Medical Center, Baton Rouge, LA 70816 Phone: 225-754-3278 | |
Dr. Tamika Session Mayo, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3401 North Blvd, Ste 360, Baton Rouge, LA 70806 Phone: 225-381-2712 Fax: 225-381-2715 | |
Gregory F Ferrara, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13828 Coursey Blvd, Baton Rouge, LA 70817 Phone: 225-751-1544 Fax: 225-751-1909 | |
James Michael Robinson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7566 Picardy Ave, Baton Rouge, LA 70808 Phone: 225-765-5500 Fax: 225-256-1400 |